Breaking News
4876 - 4890 of 6634 results
Prev
324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
Next
May 27, 2008
Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas.
This collaboratio…
Read More »
May 27, 2008
WuXi PharmaTech has named Dr. Peng Wang to the role of vice president of Discovery Biology. Dr. Wang will oversee the company's growing portfolio of discovery biology service offerings. He will report directly to Dr. Ge Li, the company's chairman and…
Read More »
May 23, 2008
Mary Haak-Frendscho, Ph.D. has been appointed president and chief scientific officer, Takeda San Francisco, Inc. Dr. Haak-Frendscho will be responsible for leading all activities at the company, including overall research and preclinical development,…
Read More »
May 23, 2008
William J. Conroy has been appointed vice president of operations and engineering at Microfluidics, a wholly owned subsidiary of MFIC Corp. In this position, Mr. Conroy will have P/L responsibility for the operating division of both Microfluidics and…
Read More »
May 23, 2008
DOR BioPharma has opened a new corporate office in the UK. The new office gives DOR a presence in the EU to better facilitate the Named Patient Access program that will be administered by IDIS, also based in the UK. Serving as the company's official…
Read More »
May 22, 2008
Norwich Pharmaceuticals, Inc. has made several appointments as part of the company's initiative to expand its contract manufacturing and packaging services. Douglas L. Drysdale has been appointed to the newly created position of chief executive offic…
Read More »
May 22, 2008
Eli Lilly and Co. has made changes across its executive leadership structure. "Earlier this year I asked each of our senior leaders to look closely at their respective areas to determine if they were optimally structured to meet the demands of o…
Read More »
May 22, 2008
Orly Zargar has been appointed the West Coast business development representative for Personal Care, BioScreen Testing Services, Inc. Ms. Zargar is responsible for supporting and contributing to the company's continued growth.
…
Read More »
May 21, 2008
Daiichi Sankyo Co., Ltd. has entered into an agreement to acquire U3 Pharma AG, a privately held German biotechnology company focusing on antibody research for the treatment of cancer. Daiichi Sankyo will purchase all of the stock and make a one-time…
Read More »
May 21, 2008
Almac Clinical Technologies, a division of the Almac Group, has signed a record $12 million worth of new studies within the past several weeks, including a global mega-study involving almost 20,000 patients.
Almac Clinical Techn…
Read More »
May 21, 2008
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. have updated the clinical development program for aflibercept, and provided results from a Phase II study in advanced ovarian cancer. The companies reported that a recent study did not achieve its pr…
Read More »
May 20, 2008
Oso Biopharmaceuticals Manufacturing, LLC has purchased the Albuquerque, NM-based sterile injectables manufacturing business of Catalent Pharma Solutions. Terms of the transaction were not disclosed.
The unit provides cGMP glass…
Read More »
May 20, 2008
Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named executive medical directors for respiratory disorders and metabolic disorders, respectively, MDS Pharma Services.
"Pharmaceutical companies are pursuing clinica…
Read More »
May 20, 2008
KAI Pharmaceuticals has initiated enrollment in a Phase I study of KAI-1678, a first-in-class, isozyme-selective inhibitor of the epsilon protein kinase C pathway. KAI-1678 has been shown to be highly effective at reducing pain responses in a wide va…
Read More »
May 19, 2008
Schering-Plough Corp. has extended its collaboration with MorphoSys AG for one year. The collaboration, announced in May 2006, has a maximum term of five years until 2011 and may be extended by SP after each year. Under the agreement, SP will continu…
Read More »
4876 - 4890 of 6634 results
Prev
324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
Next



